



IAILNI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Suresh K. Arya, Ph.D.

Application No. 10/731,988 **Filed:** December 9, 2003

Confirmation No. 9402

For: LENTIVIRUS VECTOR SYSTEM

Examiner: Myron G. Hill

Art Unit: 1648

Attorney Reference No. 4239-67517-01

COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent for Applicant(s)_

Date Mailed __June 20,

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent. This Information Disclosure Statement ("IDS") is being mailed before Applicant received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicant will provide copies of such patents or applications upon request.

Submitted herewith is a check for \$180.00 to cover the fee as required by 37 C.F.R. § 1.97(d) and as set forth in 37 C.F.R. § 1.17(p).

Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A duplicate copy of this sheet is enclosed.

06/23/2005 RMEBRAHT 00000037 10731988

01 FC:1806

- 1 -

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Sheree Lynn Rybak, Ph.

Registration No. 47,913

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 228-9446

cc: Docketing

4		OIPE		
WDN/SLR:dm	06/20/05	4239-67517/01	379365	E-231-1998/0-US-04
		- 1		ions

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Attorney Docket Number	4239-67517-01
Application Number	10/731,988
Filing Date	December 9, 2003
First Named Inventor	Arya
Art Unit	1648
Examiner Name	Myron G. Hill

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,013,516	1/11/2000	Verma et al.
	-			

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee	
		WIPO	WO 97/12622 A1	10.04.1997	The Salk Institute for Biological Studies	
Examiner's Cite No. Initials* (optional)	Cite No. (optional)	OTHER DOCUMENTS				
		Naldini et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Continual Vector," <i>Science 272</i> :263-267 (1996).				
					-	
	_					

EXAMINER DATE CONSIDERED:	
---------------------------	--

^{*} Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.